STOKStoke Therapeutics, Inc.

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date. Speaking at a Canaccord Genuity event, Chief Executive Officer Ian Smith said t

Phase III enrollment complete for zorevunersen with zero discontinuation rates.

Stoke Therapeutics (NasdaqGS:STOK) filed a shelf registration for a potential 2,000,000 common share offering reportedly tied to an Employee Stock Ownership Plan. The filing indicates possible future capital raising activity that could affect Stoke Therapeutics' capital structure and ownership mix. The ESOP related nature of the offering highlights employee equity participation as a factor in the company's compensation approach. To put this kind of equity move in context and see how other...

Moby summary of Stoke Therapeutics, Inc.'s Q2 2026 earnings call

Stoke Therapeutics Inc (STOK) reports robust financial runway and rapid Phase 3 enrollment, but key efficacy data remains pending until Q3 2027.

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company’s planned rolling new drug application submission. The global,

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.